A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) aromatase inhibitors on biomarkers in post-menopausal women with hormone receptor positive locally advanced breast cancer (LABC)

被引：0
|
作者：
Freedman, O. [1 ]
Amir, E. [1 ]
Dranitsaris, G. [1 ]
Dowsett, M. [2 ]
Cole, D. E. C. [3 ]
Hanna, W. [4 ]
O'Malley, F. [5 ]
Folkerd, E. [2 ]
Verma, S. [4 ]
Clemons, M. J. [1 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada
[4] Odette Canc Ctr, Toronto, ON, Canada
[5] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70919-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [41] PROGRESSION-FREE SURVIVAL WITH ENDOCRINE-BASED THERAPIES FOLLOWING PROGRESSION ON AN NON-STEROIDAL AROMATASE INHIBITOR AMONG POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER: A NETWORK META-ANALYSIS
    Ayyagari, R.
    Tang, D.
    Patterson-Lomba, O.
    Zhou, Z.
    Xie, J.
    Niravath, P. A.
    VALUE IN HEALTH, 2017, 20 (05) : A5 - A5
  • [42] Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
    Kimberly Blackwell
    Howard Burris
    Patricia Gomez
    N. Lynn Henry
    Steven Isakoff
    Frank Campana
    Lei Gao
    Jason Jiang
    Sandrine Macé
    Sara M. Tolaney
    Breast Cancer Research and Treatment, 2015, 154 : 287 - 297
  • [43] Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
    Blackwell, Kimberly
    Burris, Howard
    Gomez, Patricia
    Henry, N. Lynn
    Isakoff, Steven
    Campana, Frank
    Gao, Lei
    Jiang, Jason
    Mace, Sandrine
    Tolaney, Sara M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (02) : 287 - 297
  • [44] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial
    Harbeck, N.
    Vazquez, R. Villanueva
    Tripathy, D.
    Lu, Y.
    De Laurentiis, M.
    Kuemmel, S.
    Taylor, D.
    Bardia, A.
    Hurvitz, S.
    Chow, L.
    Im, S.
    Franke, F.
    Hughes, G.
    Miller, M.
    Kong, O.
    Chandiwana, D.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S3 - S3
  • [45] Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
    Noguchi, Shinzaburo
    Ellis, Matthew J.
    Robertson, John F. R.
    Thirlwell, Jackie
    Fazal, Mehdi
    Shao, Zhimin
    BREAST CANCER, 2018, 25 (03) : 356 - 364
  • [46] Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)
    Shinzaburo Noguchi
    Matthew J. Ellis
    John F. R. Robertson
    Jackie Thirlwell
    Mehdi Fazal
    Zhimin Shao
    Breast Cancer, 2018, 25 : 356 - 364
  • [47] PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
    Turner, Nicholas C.
    Ro, Jungsil
    Andre, Fabrice
    Loi, Sherene
    Verma, Sunil
    Iwata, Hiroji
    Harbeck, Nadia
    Loibl, Sibylle
    Bartlett, Cynthia Huang
    Zhang, Ke
    Giorgetti, Carla
    Randolph, Sophia
    Koehler, Maria
    Cristofanilli, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [48] Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7.
    Tripathy, Debu
    Bardia, Aditya
    Hurvitz, Sara A.
    Harbeck, Nadia
    Colleoni, Marco
    Franke, Fabio A.
    Chow, Louis W. C.
    Im, Seock-Ah
    Shao, Zhimin
    Keyserlingk, John R.
    Soler, Lidia Mongay
    Horan, Melissa
    Dhuria, Shyeilla V.
    Hughes, Gareth
    Lu, Yen-Shen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
    Turner, Nicholas C.
    Ro, Jungsil
    Andre, Fabrice
    Loi, Sherene
    Verma, Sunil
    Iwata, Hiroji
    Harbeck, Nadia
    Loibl, Sibylle
    Huang, Cynthia
    Zhang, Bartlett Ke
    Giorgetti, Carla
    Randolph, Sophia
    Koehler, Maria
    Cristofanilli, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis
    Hurvitz, Sara A.
    Wheatley-Price, Paul
    Tripathy, Debu
    Lu, Yen-Shen
    Chow, Louis
    Bachelot, Thomas Denis
    Hegg, Roberto
    Chia, Stephen K. L.
    Yardley, Denise A.
    Kong, Oliver
    Alam, Jahangir
    Diaz-Padilla, Ivan
    Baeck, Johan
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345